Published in Mol Psychiatry on January 10, 2017
AMPA receptor trafficking and synaptic plasticity. Annu Rev Neurosci (2002) 13.09
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry (2006) 11.84
mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists. Science (2010) 10.97
Antidepressant effects of ketamine in depressed patients. Biol Psychiatry (2000) 10.91
Cellular mechanisms underlying the antidepressant effects of ketamine: role of alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptors. Biol Psychiatry (2007) 6.59
NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses. Nature (2011) 6.40
A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression. Arch Gen Psychiatry (2010) 4.85
NMDAR inhibition-independent antidepressant actions of ketamine metabolites. Nature (2016) 3.18
Ketamine and Other NMDA Antagonists: Early Clinical Trials and Possible Mechanisms in Depression. Am J Psychiatry (2015) 3.07
Glutamate-based antidepressants: 20 years on. Trends Pharmacol Sci (2009) 2.20
Ketamine and the next generation of antidepressants with a rapid onset of action. Pharmacol Ther (2009) 1.90
Inhibition of glycogen synthase kinase-3 is necessary for the rapid antidepressant effect of ketamine in mice. Mol Psychiatry (2011) 1.86
GLYX-13, a NMDA receptor glycine-site functional partial agonist, induces antidepressant-like effects without ketamine-like side effects. Neuropsychopharmacology (2012) 1.74
Synaptic mechanisms underlying rapid antidepressant action of ketamine. Am J Psychiatry (2012) 1.69
The role of glutamate in mood disorders: results from the ketamine in major depression study and the presumed cellular mechanism underlying its antidepressant effects. Curr Psychiatry Rep (2007) 1.50
Acute suppression of spontaneous neurotransmission drives synaptic potentiation. J Neurosci (2013) 1.43
Ketamine and rapid-acting antidepressants: a window into a new neurobiology for mood disorder therapeutics. Annu Rev Med (2014) 1.39
Sub-anesthetic concentrations of (R,S)-ketamine metabolites inhibit acetylcholine-evoked currents in α7 nicotinic acetylcholine receptors. Eur J Pharmacol (2012) 1.32
Allosteric modulators for the treatment of schizophrenia: targeting glutamatergic networks. Curr Top Med Chem (2013) 1.28
Anti-anhedonic effect of ketamine and its neural correlates in treatment-resistant bipolar depression. Transl Psychiatry (2014) 1.14
The role of the tripartite glutamatergic synapse in the pathophysiology and therapeutics of mood disorders. Neuroscientist (2009) 1.13
Ketamine and other N-methyl-D-aspartate receptor antagonists in the treatment of depression: a perspective review. Ther Adv Chronic Dis (2015) 0.98
Ketamine and other potential glutamate antidepressants. Psychiatry Res (2014) 0.96
Developing biomarkers in mood disorders research through the use of rapid-acting antidepressants. Depress Anxiety (2013) 0.95
Rapid antidepressant effects: moving right along. Mol Psychiatry (2013) 0.93
Neural correlates of change in major depressive disorder anhedonia following open-label ketamine. J Psychopharmacol (2015) 0.91
Examination of Org 26576, an AMPA receptor positive allosteric modulator, in patients diagnosed with major depressive disorder: an exploratory, randomized, double-blind, placebo-controlled trial. J Psychopharmacol (2012) 0.90
Emerging treatment mechanisms for depression: focus on glutamate and synaptic plasticity. Drug Discov Today (2016) 0.90
Enhancing AMPA to NMDA throughput as a convergent mechanism for antidepressant action. Drug Discov Today Ther Strateg (2006) 0.87
Comparison of R-ketamine and rapastinel antidepressant effects in the social defeat stress model of depression. Psychopharmacology (Berl) (2016) 0.83
AMPA Receptor-mTOR Activation is Required for the Antidepressant-Like Effects of Sarcosine during the Forced Swim Test in Rats: Insertion of AMPA Receptor may Play a Role. Front Behav Neurosci (2015) 0.82
New targets for rapid antidepressant action. Prog Neurobiol (2015) 0.81
Ketamine-induced inhibition of glycogen synthase kinase-3 contributes to the augmentation of α-amino-3-hydroxy-5-methylisoxazole-4-propionic acid (AMPA) receptor signaling. Bipolar Disord (2016) 0.79
An assessment of the anti-fatigue effects of ketamine from a double-blind, placebo-controlled, crossover study in bipolar disorder. J Affect Disord (2016) 0.78
Animal models to improve our understanding and treatment of suicidal behavior. Transl Psychiatry (2017) 0.76
Acute ketamine administration corrects abnormal inflammatory bone markers in major depressive disorder. Mol Psychiatry (2017) 0.75